Ultime notizie per Onto Innovation (NYSE:ONTO) Azioni

ONTO INNOVATION INC

Onto Innovation

Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.

Sep,12,,2019,Santa,Clara, - ,Ca, - ,Usa,-

News

Markets

Media

Trading Ideas

ASML

LRCX

ONTO

ORLY

Il noto conduttore di &#34;Mad Money&#34; esprime pareri negativi su quattro società, offrendo però valide alternative d&#39;investimento per ciascuna.

Jim Cramer scatenato: no a questo titolo perché verrà frazionato

Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 5 years by 14.01% on an annualized basis producing an average annual return of 28.08%. Currently, Ameriprise Finl has a market capitalization of $51.55 billion. 
Buying $1000 In AMP: If an investor had bought $1000 of AMP stock 5 years ago, it would be worth $3,513.05 today based on a price of $539.82 for AMP at the time of writing.
<h3>Ameriprise Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752853523_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

There is a long tradition of high-profile businessmen owning professional sports franchises, but<a href="https://www.benzinga.com/tech/25/05/45221263/blackstone-cofounder-calls-recognizing-opportunity-pattern-recognition-focus-on-what-doesnt-make-sense"> Blackstone</a> (NYSE:<a href="https://www.benzinga.com/quote/BX"> BX</a>) executive David Blitzer has taken that trend to a new level. According to <a href="https://www.businessinsider.com/david-blitzer-blackstone-sports-investing-teams-nba-nhl-mlb-mls-2025-6">Business Insider</a>, Blitzer is the first person to own an equity share of a team in all five major U.S. men's sports leagues. Although owning pro-sports franchises carries an undeniable "cool factor," Blitzer's involvement in sports is based on his belief in the industry's growth potential.
That's not to say that he isn't a sports fan. &#8220;I thought I was good when I was, you know, like a teenager. Then I realized by high school that I was adequate at best and certainly was not playing past high school,&#8221; he told Bloomberg's "<a href="https://www.youtube.com/watch?v=mQ-wWREEuIA">The Deal</a>" podcast. Blitzer may not have possessed the athletic prowess to be a top player, but he never lost his passion for sports.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to grab <a href="https://www.benzinga.com/money/mode-mobile-2">4,000 of its pre-IPO shares for just $0.30/share</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
He made his name as an investor with Blackstone, and then pro sports began gravitating in his direction. Ownership of major sports franchises is increasingly becoming a billionaire's playground. There is a limited supply of teams, and a growing list of billionaires who want to buy in. That lack of supply and high demand is combining to drive the value of professional sports teams through the roof.
Look no further than the Buss family as an example. They recently struck a deal to sell their majority stake in the Los Angeles Lakers for $10 billion. Purchase prices like that are increasingly putting pro-sports ownership into private equity territory. Blitzer has the home-field advantage there. Blitzer's involvement with sports ownership began in 2011. He joined forces with Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) co-founder Josh Harris to form Harris-Blitzer Sports and Entertainment, which bought the NBA's Philadelphia 76ers for $280 million.
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
&#8220;We had a lot of experience in corporate carve-outs. We had a lot of experience in bringing in new management teams and thinking about incentive structures in ways that I don&#8217;t really think sports had really done in the past,&#8221; Blitzer told "The Deal." Harris-Blitzer also purchased a share of the NHL's New Jersey Devils. Blitzer's portfolio includes stakes in the NFL's Washington Commanders, MLB's Cleveland Guardians and MLS' Real Salt Lake.
According to Business Insider, Blitzer's combined ownership makes him the first person to own equity stakes across all five leagues. However, it was strategy, not ego, that motivated Blitzer to diversify his sports franchise portfolio so heavily. Owning shares in multiple teams allows him to leverage multiteam advertising partnerships with advertisers. It's an attractive package that Blitzer's contemporaries who own one or two clubs can't match.
See Also: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
A recent promotional partnership between<a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45752995/soup-stock-sours-analyst-wary-of-campbells-snack-woes-as-tariffs-weigh-on-profitability"> Campbell&#8217;s soup</a> (NYSE:<a href="https://www.benzinga.com/quote/CPB"> CPB</a>), the Devils, the Commanders, the 76ers, and Joe Gibbs Racing is a perfect example of the unique deals Blitzer can leverage.&nbsp; &#8220;These are content and media businesses, and they have some of the best IP in the world. And frankly, in today&#8217;s world, when you think about live content, there&#8217;s probably nothing more valuable,&#8221; Blitzer told The Deal.
Blitzer isn't resting on his laurels either. According to Business Insider, he has turned his attention to youth sports. In May, he and Harris launched<a href="https://www.prnewswire.com/news-releases/josh-harris--david-blitzer-launch-unrivaled-sports-and-take-significant-strategic-investment-from-the-chernin-group-302100481.html"> Unrivaled Sports</a>. Unrivaled Sports will operate 15 youth sports facilities, including baseball fields and action sports academies. MLB Hall-of-Famer Cal Ripken Jr. will assist Unrivaled Sports with youth baseball development, and Olympic gold medalist Shaun White will advise on action sports.
Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>&nbsp;
Image: Shutterstock

A League Of His Own—Blackstone Bigwig Becomes First Person To Own Stake In Teams All 5 Major U.S. Men's Sports Leagues

RITR

Reitar Logtech Shares Halted On Circuit Breaker To The Downside, Stock Now Down -6.34%

WIIM

Abbott Laboratories shares are trading higher after Jefferies upgraded the stock from hold to buy and raised the price target from $143 to $145. The move may also reflect a rebound following Thursday's drop on weak guidance.

DELL

Dell Technologies shares are trading higher after B of A Securities raised its price target from $155 to $165 while maintaining a buy rating.

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company&#8217;s recent efforts to provide clarity on its <a href="https://www.benzinga.com/news/fda/25/07/46473418/sarepta-therapeutics-reorganization-boosts-investor-confidence">restructuring</a> and FDA label plans. 
The <a href="https://www.statnews.com/2025/07/18/sarepta-gene-therapy-muscular-dystrophy-limb-girdle-patient-death/">latest</a> fatality, a 51-year-old man participating in a clinical trial for SRP-9004, the company's gene therapy for the treatment of limb-girdle muscular dystrophy (LGMD) type 2D/R3, suffered acute liver failure, a cause of death also reported in two earlier fatalities associated with Sarepta&#8217;s approved <a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy">Duchenne muscular dystrophy treatment</a>, Elevidys.
The update was <a href="https://www.biocentury.com/article/656520/third-death-from-a-sarepta-gene-therapy" target="_blank" rel="noreferrer noopener">first</a> reported by the BioCentury website on Thursday. 
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a>
Just a day before, the investors cheered as the company issued an update on ongoing label expansion efforts for Elevidys (delandistrogene moxeparvovec-rokl). 
In response to these safety concerns, the U.S Food and Drug Administration (FDA) has requested that the label include a black box warning for acute liver injury (ALI) and acute liver failure (ALF), a change with which Sarepta has agreed.
This agreement appears to resolve any major issues with the label for the ambulant portion of the Elevidys patient population. In June, Sarepta temporarily suspended shipments of Elevidys for <a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" target="_blank" rel="noreferrer noopener">non-ambulatory patients</a>.
Notably, the company did not disclose the third patient death in its recent business update. However, Sarepta reported it planned to deprioritize the development of its LGMD franchise, with the exception of SRP-9003 for LGMD 2E/R4, suggesting the patient death could have played a role in the company's pipeline reprioritization.
Sarepta reprioritized its pipeline and paused several programs, including gene therapies in development for limb-girdle muscular dystrophy (LGMD). Sarepta is expected to submit the Biologics License Application for SRP-9003 for LGMD type 2E/R4 later this year.
William Blair analysts, commenting on the situation, noted that the patient death is &#8220;unfortunate and concerning, particularly since it occurred with one of the company&#8217;s other gene therapies.&#8221; 
They suggested that, given the patient&#8217;s age, the acute liver failure was likely also caused by high-dose, systemic adeno-associated virus (AAV) delivery, a common vector for gene therapies. 
Analyst Sami Corwin emphasized the uncertainty surrounding whether Sarepta will release more information about this latest patient death or when the FDA might respond to the broader safety concerns.
Despite the halted development of SRP-9004, Corwin added in an investor note on Friday that this incident could still raise concerns about the safety of SRP-9003 as it progresses toward potential approval, potentially impacting its commercial appeal. 
The death in the LGMD trial might also increase patient hesitancy to use the already approved Elevidys and could further diminish overall investor confidence in Sarepta.
Due to ongoing doubts about the long-term success of Sarepta's gene therapy and PMO platform programs, William Blair sees limited short-term upside on the stock and maintains <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings" target="_blank" rel="noreferrer noopener">a Market Perform rating</a>.
Bank of America Securities also remains Neutral on Sarepta Therapeutics, lowering its price target from $28 to $20. Oppenheimer, while maintaining an Outperform rating for Sarepta Therapeutics, has similarly lowered its price forecast from $45 to $41.
Price Action: SRPT stock is trading lower by 15.5% to $18.57 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/07/46493214/exxons-block-fails-chevron-seals-53-billion-hess-deal-after-ruling" target="_blank" rel="noreferrer noopener">Exxon&#8217;s Block Fails—Chevron Seals $53 Billion Hess Deal After Ruling</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Health Care

Price Target

Analyst Ratings

Movers

General

SRPT

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Barclays analyst Jared Shaw maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Underweight and raises the price target from $78 to $82.

TCBI

Barclays Maintains Underweight on Texas Capital Bancshares, Raises Price Target to $82

Barclays analyst Nicholas Campanella maintains Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) with a Overweight and raises the price target from $269 to $359.

Barclays Maintains Overweight on Talen Energy, Raises Price Target to $359

Barclays analyst Ramsey El-Assal maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Overweight and raises the price target from $80 to $90.

PYPL

Barclays Maintains Overweight on PayPal Holdings, Raises Price Target to $90

Barclays analyst Benjamin Budish maintains Interactive Brokers Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) with a Overweight and raises the price target from $65 to $73.

IBKR

Barclays Maintains Overweight on Interactive Brokers Group, Raises Price Target to $73

Barclays analyst Christine Cho maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Equal-Weight and raises the price target from $164 to $170.

GNRC

Barclays Maintains Equal-Weight on Generac Hldgs, Raises Price Target to $170

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and lowers the price target from $40 to $26.

CDNA

Craig-Hallum Maintains Buy on CareDx, Lowers Price Target to $26

Bank of America analysts are ramping up expectations for Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), forecasting above-consensus earnings on strong artificial intelligence tailwinds, ad recovery and robust enterprise software demand heading into quarterly <a href="https://www.benzinga.com/earnings">results later this month.</a>
<h3 class="wp-block-heading">Alphabet Expected To Outperform On Search and FX Tailwinds</h3>
Alphabet reports its second-quarter results on July 23, and Bank of America analyst Justin Post said the stock looks well-positioned to beat expectations, driven by ad strength, macroeconomic tailwinds, and product monetization improvements from AI.
Post revised its revenue and earnings estimate to $81 billion and $2.21 per share, up from prior forecasts of $80 billion and $2.15. Wall Street consensus sits lower at $79.5 billion and $2.15.
Alphabet's core search revenue is expected to rise 11% year-over-year, ahead of Street estimates of 9%.
Search revenue has been the most closely watched—and arguably the most feared—metric for investors, as the rise of AI platforms threatens to bypass traditional search engines and disrupt Google&#8217;s core business model.
"We think Street estimates for Search… have upside," Post said, citing stable spending trends and FX that could add two points of growth. 
He also indicated that the company's AI-driven features, like AI Overviews and AI Mode, are reducing click volumes but improving conversion rates, which is ultimately a monetization win.
Cloud revenue is forecasted at $13.2 billion, modestly above the $13.1 billion Street view, with additional upside potential from price hikes in Workspace. 
Post raised the price target from $200 to $210, implying a 14% upside from current levels. The analyst flagged that Alphabet trades at an attractive 12x multiple on 2026 core Google earnings, compared to 21x for the S&amp;P 500.
Alphabet stock is up 10% since its I/O conference on May 20, but remains down 2.4% year-to-date. Notably, Alphabet has underperformed compared to the Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>), which has risen 5% year-to-date.
<h3 class="wp-block-heading">Microsoft Gets Lift from Azure Strength And Copilot Uptake</h3>
Microsoft reports its fiscal fourt-quarter results on July 30, and the firm analyst Brad Sills said checks with partners show steady demand trends, particularly for Azure and enterprise software like Office.
Azure is projected to grow 35.5% year-over-year in constant currency, driven by cloud migrations, security needs, and AI services.
In Microsoft's productivity and business processes segment, Office growth could reach 15% versus the previously guided 14%, thanks to commercial upgrades and the growing adoption of Copilot, Microsoft's generative AI assistant. The firm also sees upside in PC shipments, which tracked 7% year-over-year in the second quarter, outperforming the 4% expected.
Looking further ahead, Sills expects Microsoft's revenue to grow 14% in fiscal 2026, the same pace as in 2025, with Azure taking up a larger share. However, margins might flatten as capital expenditures (capex) ramps—forecasted to hit $99.1 billion, roughly 31% of revenue.
Sills said the next big test will be whether Copilot drives incremental top-line growth. 
"While an inflection quarter is unlikely, we believe Copilot has potential to drive incremental growth as we move through FY26."
Microsoft stock has rallied 22% in 2025, trailing only Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&#8217;s 28% rally in the Magnificent Seven group.
Bank of America reiterated its Buy rating and lifted the price target from $515 to $585, implying a 15% upside from current levels. 
Price Action: Alphabet shares were up 0.62% at $184.71 and Microsoft shares were down 0.32% at $510.08 at the time of publication Friday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46477275/wall-street-big-7-are-now-bigger-than-chinas-entire-economy">Wall Street&#8217;s Big 7 Are Now Bigger Than China&#8217;s Entire Economy</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Macro Economic Events

Economics

Tech

GOOGL

MAGS

MSFT

NVDA

These Two Magnificent 7 Stocks Are About To Hit Overdrive — And Wall Street's Getting Excited

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $434 to $358.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $358

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 5 years by 10.74% on an annualized basis producing an average annual return of 24.8%. Currently, Live Nation Entertainment has a market capitalization of $35.28 billion. 
Buying $1000 In LYV: If an investor had bought $1000 of LYV stock 5 years ago, it would be worth $3,025.60 today based on a price of $150.72 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752852611_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Live Nation Entertainment 5 Years Ago Would Be Worth This Much Today

Barclays analyst Jason Goldberg maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Equal-Weight and raises the price target from $49 to $55.

Barclays Maintains Equal-Weight on Citizens Financial Group, Raises Price Target to $55

COIN

HOOD

Shares of Robinhood and Coinbase shares are trading higher following reports indicating President Trump is set to open the US retirement plans to crypto investments. Additionally, the US House passed the CLARITY Act on Thursday.

Barclays analyst Brandt Montour maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and raises the price target from $101 to $127.

WYNN

Barclays Maintains Overweight on Wynn Resorts, Raises Price Target to $127

Barclays analyst Brandt Montour maintains MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Overweight and raises the price target from $43 to $44.

Barclays Maintains Overweight on MGM Resorts International, Raises Price Target to $44

A <a href="https://www.benzinga.com/news/politics/25/07/46491369/cbs-to-end-stephen-colberts-the-late-show-in-2026-days-after-he-called-the-trump-paramount-deal-a-big-fat-bribe" target="_blank" rel="noopener">decision to cancel</a> the "Late Show With Stephen Colbert" is prompting members of Congress to speak out, as the timing draws attention to a recent settlement between Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) and President Donald Trump.
What Happened: Paramount, which owns the CBS network, has confirmed plans to end the "Late Show" in May 2026, news that comes after the media company<a href="https://www.benzinga.com/news/legal/25/07/46212970/trump-wins-16-million-settlement-from-paramount-over-cbs-60-minutes-kamala-harris-interview-but-no-apology-issued"> settled a lawsuit with Trump</a> surrounding a "60 Minutes" interview with Democratic presidential candidate Kamala Harris.
Paramount previously called the Trump lawsuit meritless before agreeing to pay $16 million to settle it.
Stephen Colbert, who has hosted the "Late Show" since 2015, recently said the settlement could be a "big fat bribe." Days later, he announced to his audience that the show was ending.
Members of Congress are speaking out, questioning the timing of the cancellation and how it may relate to Paramount&#8217;s efforts to win over Trump as the company pushes through its merger with Skydance. This merger still requires approval from the Trump administration.
Senator Elizabeth Warren (D-Mass.) tweeted about the questionable timing.
"CBS canceled Colbert's show just THREE DAYS after Colbert called out CBS parent company Paramount for its $16M settlement with Trump – a deal that looks like bribery. America deserves to know if his show was canceled for political reasons. Watch and share his message," Warren <a href="https://x.com/SenWarren/status/1946003619821580369">tweeted</a>, sharing Colbert's message to his audience.
Senator Adam Schiff (D-Calif.) was a recent guest on the "Late Show" and also referred to the timing in a tweet.
"Just finished taping with Stephen Colbert who announced his show was cancelled. If Paramount and CBS ended the Late Show for political reasons, the public deserves to know. And deserves better," Schiff <a href="https://x.com/SenAdamSchiff/status/1945991349339042169">tweeted</a>.
Senator Martin Heinrich (D-N.M.) shared a CNN link to the cancellation news and leveled a rather blunt allegation.
"CBS sells out…again," Heinrich <a href="https://x.com/SenatorHeinrich/status/1946007327804449267">tweeted</a>.
Rep. Pramila Jayapal (D-Wash.), like Warren, also said that Americans deserve to know if politics influenced the decision.
"Stephen Colbert's show was canceled three days after he called out Paramount, CBS's parent company, for folding to Trump with a $16M settlement for a lawsuit that even they called ‘without merit.' People deserve to know if this is a politically motivated attack on free speech," Jayapal <a href="https://x.com/RepJayapal/status/1946037531948073145">tweeted</a>.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45363944/cbs-highlights-tv-dominance-17-year-streak-on-top-can-success-help-offset-trump-merger-concerns">CBS Highlights TV Dominance, 17-Year Streak On Top: Can Success Help Offset Trump, Merger Concerns?</a>
Why It's Important: Live television has faced declining ratings in the era of streaming, especially late-night non-sports programming. The decision to cancel a late-night talk show may, in fact, be a "financial decision."
The timing of the decision will likely continue to raise red flags and be a major talking point ahead of the merger with Skydance.
"This is purely a financial decision against a challenging backdrop in late night. It is not related in any way to the show's performance, content or other matters happening at Paramount," the company stated.
Paramount's decision comes after the settlement with Trump, and as Warren<a href="https://www.benzinga.com/news/politics/25/07/46457142/elizabeth-warren-has-the-receipts-bribery-in-plain-sight-funding-trumps-library"> has accused the media company </a>and others of "bribery in plain sight."
In a recent report, Warren stated that over $63 million has been donated to Donald Trump&#8217;s future presidential library by companies that may be doing so to gain favor with the president today.
&#8220;The timing of these donations — coming while Trump sits in office and makes critical decisions that may impact the same donors — raises serious ethical concerns about potential bribery and influence-peddling,&#8221; Warren said.
Paramount was named in the report, with the $16 million settlement being donated to the presidential library.
&#8220;We could be seeing giant companies like Paramount and Meta and foreign countries like Qatar pay Trump off in plain sight. Government should work for the American people, not just whichever giant company or foreign government can dump the most money into the president&#8217;s future library,&#8221; Warren added.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/24/04/38148539/paramount-skydance-deal-could-be-home-run-for-shari-redstone-loss-for-shareholders-investor">Paramount, Skydance Deal Could Be &#8216;Home Run&#8217; For Shari Redstone, Loss For Shareholders, Investor Warns</a></li>
</ul>
Photo: Shutterstock

Entertainment

Politics

PARA

PARAA

Elizabeth Warren Demands Paramount Explain Colbert's 'Late Show' Cancellation—'America Deserves To Know'

Press Releases

Onto Innovation to Participate in 27th Annual Needham Growth Conference

Onto Innovation Receives Volume Purchase Agreement from a Leading DRAM Manufacturer for Metrology Product Suite

Onto Innovation Advances Process Control Suite for 3D Interconnect Yields

Onto Innovation to Report Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

Onto Innovation Reports 2024 Fourth Quarter and Full Year Results

Onto Innovation to Report First Quarter 2025 Financial Results on May 8, 2025

Onto Innovation Reports 2025 First Quarter Results

Onto Innovation to Participate in Upcoming Investor Events

Onto Innovation Enhances Leadership Team with Two Senior Executive Appointments

Onto Innovation Announces Agreement to Acquire Semilab International's Materials Analysis Business

Axcelis Technologies, Inc. - Common Stock

Axcelis Technologies

ACM Research, Inc. - Class A Common Stock

ACM Research

Aehr Test System

Aeluma

Applied Mat

Amkor Tech

ASML Holding N.V. - New York Registry Shares

ASML Holding

Atomera

Cohu

DAQO New Energy Corp. American Depositary Shares, each representing five ordinary shares

Comments

Onto Innovation

Notizie

Ultime notizie per Onto Innovation (NYSE:ONTO) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO